4 stories mentioning PGENUpdated 28d ago
Every FINWIRES story that references PGEN, newest first.
Harry Thomasian Jr., Chief Financial Officer, on June 29, 2026, sold 200,000 shares in Precigen (PGEN) for $1,113,143. Following the Form 4 filing with the SEC, Thomasian has control over a total of 354,535 common shares of the company, with 354,535 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1356090/000095010326009980/xslF345X05/ownership.xml
Helen Sabzevari, President and Chief Executive Officer, on June 29, 2026, sold 346,836 shares in Precigen (PGEN) for $2,042,864. Following the Form 4 filing with the SEC, Sabzevari has control over a total of 3,768,872 common shares of the company, with 3,768,872 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1356090/000095010326009978/xslF345X05/ownership.xml
Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) 0.6% higher.Precigen (PGEN) shares were up more than 3% after the company said the US Food and Drug Administration granted orphan drug exclusivity for its recurrent respiratory papillomatosis treatment called papzimeos.Zymeworks' (ZYME) drug to treat certain reproductive tract cancers has shown promise in early testing, the biotechnology company reported at the European Society for Medical Oncology Gynaecological Cancers Congress. Zymeworks stock was up more than 1% pre-bell.Elicio Therapeutics (ELTX) shares were down more than 64% after the company said its Phase 2 clinical study evaluating the experimental pancreatic cancer therapy ELI-002 7p did not meet the pre-specified primary endpoint of disease-free survival.
Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) 0.6% higher.Precigen (PGEN) shares were up more than 3% after the company said the US Food and Drug Administration granted orphan drug exclusivity for its recurrent respiratory papillomatosis treatment called papzimeos.
